Financing repurposed drugs for rare diseases: a case study of Unravel Biosciences

BACKGROUND: We consider two key challenges that early-stage biotechnology firms face in developing a sustainable financing strategy and a sustainable business model: developing a valuation model for drug compounds, and choosing an appropriate operating model and corporate structure. We use the speci...

Descripción completa

Detalles Bibliográficos
Autores principales: Abouarab, Bechara, Bazarian, Christian, Ben Chaouch, Zied, Lo, Andrew W., Mourenza Gonzalez, Guillermo, Novak, Richard, Vigneault, Frederic
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496212/
https://www.ncbi.nlm.nih.gov/pubmed/37700316
http://dx.doi.org/10.1186/s13023-023-02753-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10496212/
https://www.ncbi.nlm.nih.gov/pubmed/37700316
http://dx.doi.org/10.1186/s13023-023-02753-y

Ejemplares similares